HFA Icon

Valeant Raises Cash Portion of Allergan Offer As Stock Price Sinks

HFA Padded
Mark Melin
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) raised the stakes in its hostile bid for Allergan, Inc. (NYSE:AGN), to $58.30 per share, bringing the total bid to $166.16 per share while at the same time executing a separate deal with Nestle to shed some of Valeant’s skin care products and raise cash.

valeant logo
valeant

After upping cash portion, deal for Allergan still highly dependent on Valeant stock value

In upping the ante in the cash portion of a $50.4 billion cash and stock deal, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) seeks to mitigate claims the stock portion of the Valeant...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.